ZOLGENSMA

Indicated For

Spinal Muscular Atrophy (SMA)

About This Medication

# Novartis Patient Support Patient Guide: How to Get ZOLGENSMA (onasemnogene abeparvovec-xioi) at Low or No Cost ZOLGENSMA (onasemnogene abeparvovec-xioi) is a one-time gene therapy for children with spinal muscular atrophy (SMA), and the **Novartis Patient Support** program helps eligible families access it through financial assistance, insurance navigation, and dedicated case coordinators.[1][2][3] ## About ZOLGENSMA **ZOLGENSMA** is an FDA-approved gene therapy designed to treat spinal muscular atrophy (SMA) Type 1 in children under 2 years old, with expanded use for other types in younger patients. SMA is a rare genetic disease that causes muscle weakness and can lead to life-threatening complications like breathing difficulties. Unlike ongoing treatments, ZOLGENSMA is administered as a single intravenous infusion, delivering a functional copy of the SMN1 gene to motor neuron cells to help produce the survival motor neuron (SMN) protein essential for muscle function.[2][3][6] This therapy aims to address the root cause of SMA, potentially improving motor milestones and survival rates when given early. However, it's expensive—often costing over $2 million—making patient support programs crucial. Novartis Patient Support coordinates everything from insurance verification to financial aid, ensuring families focus on their child's care rather than logistics.[2][3] ## Who Qualifies for Novartis Patient Support? The program is available for **qualified patients** prescribed ZOLGENSMA, primarily focusing on U.S. residents. It supports families navigating high costs through two main financial arms: - **ZOLGENSMA CopayAssist™ Program**: For **commercially insured** patients, helping with copays, coinsurance, or deductibles. - **Novartis Patient Assistance Program (NPAP)**: For uninsured or underinsured patients meeting income guidelines, potentially providing ZOLGENSMA at no cost.[2][3] **Case Coordinators** assign a dedicated contact to guide you, answering SMA/ZOLGENSMA questions, explaining treatment steps, and tracking from prescription to delivery.[1][2][3] ## Income Eligibility Breakdown Specific income thresholds aren't publicly detailed and vary by program component—your Case Coordinator assesses eligibility based on household income, size, and situation. The Novartis Patient Assistance Program generally follows federal poverty level (FPL) guidelines, often up to 400-500% FPL for rare disease therapies, but confirmation is needed per case.[3] Here's a general overview (contact program for exacts): | Household Size | Estimated Max Income (Annual, USD) | Notes | |---------------|-----------------------------------|-------| | Individual | Not specified | Assessed case-by-case [3] | | Couple | Not specified | Varies by FPL [3] | | Family of 3 | Not specified | Qualified patients only [3] | | Family of 4 | Not specified | Call for details [2] | **Notes**: No fixed FPL% listed; program emphasizes 'qualified patients.' Provide recent tax returns, pay stubs, or proof of income during enrollment. Commercial insurance often prioritizes CopayAssist regardless of income.[1][2][3] ## Insurance Requirements - **Commercially insured patients** may qualify for CopayAssist to cover out-of-pocket costs.[2][3] - Program verifies benefits, handles **prior authorizations (PA)**, appeals, and reimbursement.[2][3][6] - **Medicare/Medicaid**: Generally ineligible for CopayAssist; NPAP may help underinsured, but government insurance often limits manufacturer assistance—confirm with coordinator.[2] - Uninsured? NPAP targets free medication for qualifiers.[3] Novartis coordinates with all payers, shipping to physician offices post-approval.[2] ## Step-by-Step Application Process 1. **Get Prescribed**: Your child's doctor prescribes ZOLGENSMA after confirming SMA diagnosis and eligibility (e.g., lab tests like SMN1/SMN2).[6] 2. **Enroll in Novartis Patient Support**: Doctor submits: - **ZOLGENSMA Prescription Form** (includes patient info, prescriber details).[7] - **START Form** (enrolls you; includes DOB, contacts).[1][5] - **Patient Authorization and Additional Consents Form** (allows Novartis to contact providers, manage support, CopayAssist).[4][5][7] Fax to 1-855-951-4363 or upload at www.zolgensma-enrollment.com.[1][4][8] 3. **Meet Your Case Coordinator**: Assigned post-enrollment for personalized guidance (Mon-Fri, 8 AM-8 PM ET). Phone: **(855) 441-4363**.[2] 4. **Insurance Verification**: Coordinator checks coverage, submits PA/appeals if needed.[2][6] 5. **Financial Assessment**: Submit income docs (taxes, W-2s, insurance cards front/back). Apply for CopayAssist or NPAP.[3][9] 6. **Approval & Treatment**: Once approved, ZOLGENSMA ships to doctor's office for infusion. No reauthorization needed—it's one-time.[2] **Tip**: Start early; multiple methods (phone, upload, fax) speed things up.[1][8] ## Timeline and Delivery Processing time varies by insurance complexity—days to weeks for verification/PA. Coordinators track progress and send reminders.[2][3] Expect: - Enrollment: Immediate upon form submission. - Benefits verification: 1-5 business days. - Financial approval: 1-2 weeks. - Delivery: Shipped frozen to **physician office** post-approval; infusion scheduled promptly.[2] Ongoing support includes pre/post-treatment reminders.[2] ## Alternatives if Denied - **Appeal Insurance Denial**: Coordinator assists with letters, peer-to-peer reviews.[2] - **Other Foundations**: Patient Access Network (PAN), HealthWell Foundation for SMA (check eligibility separately). - **Clinical Trials**: Search ClinicalTrials.gov for SMA studies. - **State Programs**: Medicaid expansions or rare disease funds. - No biosimilars exist for ZOLGENSMA.[3] Contact coordinator for tailored options.[2] ## Disclaimer This guide is for informational purposes based on available program details as of 2025. Eligibility, terms, and forms may change—**always verify with Novartis Patient Support at (855) 441-4363 or your doctor**. Not medical advice; consult healthcare providers for treatment decisions. Novartis Patient Support isn't a substitute for clinical care. Income thresholds approximate; individual assessment required. Program for U.S. residents only.[1][2][3] (Word count: 1028)

Program information last verified: March 30, 2026